Avalyn Pharma (NASDAQ:AVLN) Insider Fmr Llc Sells 53,454 Shares of Company Stock

Key Points

• FMR LLC sold 53,454 Avalyn Pharma shares at an average $30.21 each, worth about $1.61 million, reducing its ownership by 2.53%. It also sold 175,000 shares the previous day.
• Avalyn reported a quarterly loss of $0.67 per share, missing analyst expectations of a $0.64 loss.
• Analysts have a consensus “Moderate Buy” rating and a $60 average price target; the stock was trading at $30.49 in the article.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) insider Fmr Llc sold 53,454 shares of the company's stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $30.21, for a total value of $1,614,845.34. Following the transaction, the insider directly owned 2,056,081 shares of the company's stock, valued at $62,114,207.01. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Fmr Llc also recently made the following trade(s):

• On Monday, November 9th, Fmr Llc sold 175,000 shares of Avalyn Pharma stock. The stock was sold at an average price of $29.07, for a total value of $5,087,250.00.

Avalyn Pharma Stock Performance

Avalyn Pharma stock traded down $1.13 during midday trading on Thursday, reaching $30.49. The stock had a trading volume of 185,254 shares, compared to its average volume of 338,945. The stock has a market capitalization of $1.35 billion and a PE ratio of -1.34. The company's fifty day moving average is $28.87. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma Inc. has a 1-year low of $22.24 and a 1-year high of $40.17.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.03). On average, sell-side analysts anticipate that Avalyn Pharma Inc. will post -3.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AVLN. State Street Corp increased its position in shares of Avalyn Pharma by 73.7% during the 3rd quarter. State Street Corp now owns 554,004 shares of the company's stock worth $15,784,000 after purchasing an additional 235,009 shares during the last quarter. Profund Advisors LLC bought a new stake in shares of Avalyn Pharma during the 3rd quarter worth approximately $668,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Avalyn Pharma in the 3rd quarter valued at approximately $29,000. Manchester Capital Management LLC acquired a new stake in shares of Avalyn Pharma in the 3rd quarter valued at approximately $36,000. Finally, Braidwell LP acquired a new stake in shares of Avalyn Pharma in the 2nd quarter valued at approximately $26,382,000.

Analysts Set New Price Targets

A number of brokerages have recently commented on AVLN. Wall Street Zen lowered shares of Avalyn Pharma from a "hold" rating to a "sell" rating in a research report on Sunday, September 20th. Morgan Stanley raised their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Avalyn Pharma in a research note on Wednesday. Finally, Raymond James Financial assumed coverage on shares of Avalyn Pharma in a research report on Friday, October 2nd. They set an "outperform" rating and a $60.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Avalyn Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $60.00.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company's pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn's inhaled candidates are being studied as potential alternatives to oral treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.